Neramexane Dual-Receptor Action for Sub-Acute Cochlear Tinnitus
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cochlear tinnitus lack effectiveness in replicably reducing tinnitus and associated annoyance, with existing pharmaceutical approaches showing limited success due to targeting mainly the afferent part of the auditory system while neglecting efferent neurotransmission.
Innovation Solution
Administration of a 1-amino-alkylcyclohexane derivative, such as neramexane, which acts as an NMDA receptor antagonist and α9/α10 nicotinic receptor antagonist, to treat or prevent cochlear tinnitus, potentially addressing both afferent and efferent neurotransmission imbalances.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If NMDA receptor-blocking substances (acamprosate, caroverine) are used to treat tinnitus, then afferent neurotransmission is addressed, but efferent neurotransmission remains insufficiently targeted, resulting in limited treatment success
Solution Approach 1:
The patent applies universality by developing a compound (cariprazine or derivatives) that simultaneously targets multiple neurotransmission pathways - specifically acting as both an NMDA receptor antagonist (addressing afferent transmission) and an α9/α10 nicotinic receptor antagonist (addressing efferent transmission). This multi-functional approach allows a single substance to address both previously separate treatment targets, thereby improving treatment effectiveness while expanding neurotransmission coverage.
2Reliability
If treatment is delayed beyond three to twelve months of tinnitus onset, then the window for effective intervention narrows, but early treatment may not account for progressive central amplification mechanisms
Solution Approach 1:
The patent applies preliminary action by establishing that treatment within the three-to-twelve-month window addresses tinnitus before massive central amplification and pathological cognitive focusing become dominant. By intervening during this sub-acute phase, the treatment prevents the establishment of stronger maladaptive central mechanisms, thereby maintaining higher treatment efficacy while optimizing the timing window.
3Object-affected harmful factors
If outer hair cells are damaged by noise exposure, then active amplification is reduced, but uncontrolled contraction of damaged cells causes abnormal neurotransmitter release and tinnitus perception
Solution Approach 1:
The patent applies blessing in disguise by targeting the pathological consequences of noise-induced outer hair cell damage. Rather than attempting to reverse the damage itself, the invention addresses the harmful downstream effect - uncontrolled contraction leading to abnormal acetylcholine release and excessive glutamate activity. By blocking NMDA receptors and α9/α10 nicotinic receptors, the treatment converts the harmful uncontrolled cellular activity into a controlled state, eliminating tinnitus perception despite persistent cellular damage.
Data Source
Figure 1
AI summary
The present invention relates to the treatment of an individual afflicted with cochlear tinnitus comprising administering to the individual an effective amount of a 1-amino-alkylcyclohexane derivative.